Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist. With IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,420.00 | |
50 mg | 10-14 weeks | $ 3,180.00 | |
100 mg | 10-14 weeks | $ 4,300.00 |
Description | Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist. With IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW. |
Targets&IC50 | CCR5:, HIV-1 (JRFL):0.1 nM, HIV-1 (Ba-L):0.4 nM, HIV-1 (MOKW):0.2 nM |
In vitro | Aplaviroc (AK602) is identified as the most potent agent among newly designed and synthesized SDP derivatives and it also is substantially more potent than two previously published CCR5 inhibitors, E921/TAK-779 and AK671/SCH-C. Aplaviroc exerts potent activity against three wild-type R5 HIV-1 strains (HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW) with IC50 values of 0.1 to 0.4 nM and it potently blocks rgp120/sCD4 binding to CCR5 with an IC50 value of 2.7 nM. The activity of Aplaviroc's anti-HIV-1 is limited and similar to that seen for zidovudine. Aplaviroc suppresses the infectivity and replication of two HIV-1MDR variants, HIV-1MM and HIV-1JSL, at extremely low concentrations (IC50 values of 0.4 to 0.6 nM), while these two R5 HIV-1 variants are less susceptible to zidovudine, nelfinavir, and saquinavir and it also binds to CCR5 with high affinity. The Kd values thus determined for Aplaviroc, E913, E921/TAK-779, and AK671/SCH-C are 2.9±1.0, 111.7±3.5, 32.2±9.6, and 16.0±1.5 nM, respectively. These results suggest that the potent activity of Aplaviroc against R5 HIV-1 stems from its binding to ECL2B and/or its vicinity with high affinity, resulting in inhibition of gp120/CD4 binding to CCR5[1]. |
Synonyms | AK 602, GW 873140, GSK 873140 |
Molecular Weight | 577.71 |
Formula | C33H43N3O6 |
CAS No. | 461443-59-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Aplaviroc 461443-59-4 Immunology/Inflammation Microbiology/Virology Proteases/Proteasome HIV Protease CCR AK 602 GW 873140 AK-602 AK602 GW-873140 GSK 873140 GSK-873140 GSK873140 GW873140 inhibitor inhibit